the rationale for combining magrolimab with ruxolitinib in myelofibrosis
Published 1 year ago • 104 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
5:24
krt‑232: first-in-class mdm2i for myelofibrosis r/r to jak inhibitor therapy
-
1:06
fedratinib: mpn-associated myelofibrosis
-
2:33
optimizing current treatment approaches in myelofibrosis
-
2:51
bomedemstat for high-risk myelofibrosis
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
-
1:28
comorbidities and treatment decisions in myelofibrosis
-
4:48
an insight into the management of cytopenias in mf
-
2:41
novel therapies for myelofibrosis
-
2:13
exciting agents and treatment approaches emerging in the field of myelofibrosis
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis